A comprehensive view of Branded Drugs. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.
Patent Issued for Protein solution formulation containing high concentration of an anti-VEGF antibody (USPTO 11945859)
Published:
April 19, 2024
by Angiogenesis Daily
|
US Dept. of Justice files complaint alleging fraudulent drug pricing practices by Regeneron for its ophthalmology drug Eylea that cost Medicare hundreds of millions of dollars
Published:
April 12, 2024
by Zack's Commentary
|
Commentary: Excessive costs on GLP-1 medications from Eli Lilly and Novo Nordisk have led to their inaccessibility in low-/middle-income nations; report finds if branded companies were to partner with generics makers, prices could be less than US$1/month
Published:
April 08, 2024
by Indian Pharma Industry: Policies
|
FDA approves J&J’s CARVYKTI to treat patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy; an estimated 35,000 cases of the disease projected to be diagnosed this year in US
Published:
April 06, 2024
by Janssen Pharmaceutical Companies
|
Moderna COVID-19 vaccine reduces symptomatic infection in adults aged 18-19, Texas A&M University study shows; study finds slightly lower efficacy than other studies, with 53% effectiveness against infection, 71% against symptomatic illness
Published:
February 01, 2024
by Targeted News Service
|
Ask us about our Government & Public Policy market view